For complex pancreatic disease GENETIC VARIANT DESCRIPTIONS, what descriptive information shall be included in the initial publication and subsequent reports?
Considerations: This should likely include accurate MAF information for the relevant comparison populations, detailed contextual information of the comparison groups, effect prediction methods, other? Initial publication should contain replication cohort. Need consensus what other genes should be always looked at to provide genetic context. New problem: how to utilize and report exome or genome Seq data?